Foghorn Therapeutics Inc.(FHTX)

$7.07—

Chart

Foghorn Therapeutics Inc.(FHTX)

NASDAQ

$7.07—

Chart Studio

FHTX(FHTX)

FHTX

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$-0.23

Nov 4, 2026 · Reports before open

Revenue Estimate

$7M

FY2030E EPS$0.16

Analyst Sentiment

Wall St. Consensus

Buy

9 analysts·Limited coverage

Score

8 Buy (89%)1 Hold (11%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

889%

Hold

111%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$9.00

+27.3%

Consensus

$12.00

+69.7%

Bull

$20.00

+182.9%

12-Month Target Range9 analysts

$9.00$12.00$20.00

Current $7.07Consensus

Current Price

$7.07

Upside to Consensus

$4.93

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+7.12%

EPS—

FY2028

Rev+32.30%

EPS—

FY2029

Rev-21.96%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$34M	$36M	$48M	$38M	$100M
Low	$25M	$23M	$28M	$22M	$58M
High	$42M	$54M	$71M	$55M	$148M
EBITDA Avg	$-34M	$-36M	$-48M	$-38M	$-100M
Low	$-42M	$-54M	$-71M	$-55M	$-148M
High	$-25M	$-23M	$-28M	$-22M	$-58M
EBIT Avg	$-34M	$-36M	$-48M	$-38M	$-100M
Low	$-42M	$-54M	$-71M	$-55M	$-148M
High	$-25M	$-23M	$-28M	$-22M	$-58M
Net Income Avg	$-57M	$-58M	$-55M	$-40M	$10M
Low	$-82M	$-65M	$-76M	$-64M	$5M
High	$-45M	$-50M	$20M	$-18M	$17M
EPS Avg	$-0.91	$-0.94	$-0.63	$-0.63	$0.16
Low	$-1.29	$-1.03	$-1.20	$-1.02	$0.07
High	$-0.72	$-0.80	$0.31	$-0.29	$0.26
Analysts (Rev / EPS)	8 / 7	8 / 7	8 / 8	6 / 5	6 / 5

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$7M	$8M	$6M	$8M	$8M	$9M
Low	$3M	$3M	$2M	$3M	$3M	$4M
High	$11M	$11M	$8M	$12M	$12M	$13M
EBITDA Avg	$-7M	$-8M	$-6M	$-8M	$-8M	$-9M
Low	$-11M	$-11M	$-8M	$-12M	$-12M	$-13M
High	$-3M	$-3M	$-2M	$-3M	$-3M	$-4M
EBIT Avg	$-7M	$-8M	$-6M	$-8M	$-8M	$-9M
Low	$-11M	$-11M	$-8M	$-12M	$-12M	$-13M
High	$-3M	$-3M	$-2M	$-3M	$-3M	$-4M
Net Income Avg	$-17M	$-16M	$-18M	$-16M	$-18M	$-17M
Low	$-24M	$-25M	$-29M	$-27M	$-29M	$-29M
High	$-13M	$-11M	$-4M	$-4M	$-4M	$-4M
EPS Avg	$-0.24	$-0.23	$-0.25	$-0.23	$-0.25	$-0.25
Low	$-0.34	$-0.35	$-0.41	$-0.38	$-0.41	$-0.40
High	$-0.18	$-0.16	$-0.06	$-0.06	$-0.06	$-0.06
Analysts (Rev / EPS)	6 / 6	6 / 6	3 / 2	3 / 2	3 / 2	3 / 2

Earnings Surprises

Recent Analyst Actions

Feb 17, 2026Jefferies

Foghorn Therapeutics price target lowered to $12 from $14 at Jefferies

Target:$12.00

+116.2%from $5.55

Dec 18, 2025BTIG

Foghorn Therapeutics initiated with a Buy at BTIG

Target:$11.00

+137.1%from $4.64

Dec 3, 2025Stifel Nicolaus

Foghorn Therapeutics initiated with a Buy at Stifel

Target:$12.00

+170.3%from $4.44

Dec 17, 2024H.C. Wainwright

Foghorn Therapeutics price target lowered to $13 from $20 at H.C. Wainwright

Target:$13.00

+107.7%from $6.26

Sep 24, 2024Morgan Stanley

Foghorn Therapeutics (FHTX) PT Raised to $9 at Morgan Stanley

Target:$9.00

-3.4%from $9.32

Aug 19, 2024Evercore ISI

Foghorn Therapeutics initiated with an Outperform at Evercore ISI

Target:$20.00

+219.5%from $6.26

Jan 5, 2023BMO Capital

BMO Capital Initiates Coverage On Foghorn Therapeutics with Outperform Rating, Announces Price Target of $20

Target:$20.00

+206.3%from $6.53

Nov 21, 2022Morgan Stanley

Morgan Stanley Maintains Equal-Weight on Foghorn Therapeutics, Lowers Price Target to $14

Target:$14.00

+77.9%from $7.87

Aug 23, 2022Morgan Stanley

Morgan Stanley downgrades Foghorn on uncertainty from clinical hold

Target:$15.00

+37.7%from $10.89

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance